Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Añadir filtros








Intervalo de año
1.
Gut and Liver ; : 126-128, 2012.
Artículo en Inglés | WPRIM | ID: wpr-211728

RESUMEN

Hereditary fructose intolerance is an autosomal recessive disorder that is caused by a deficiency in fructose-1-phosphate aldolase (Aldolase B). Children can present with hypoglycemia, jaundice, elevated liver enzymes and hepatomegaly after intake of dietary fructose. Long-term intake of fructose in undiagnosed patients can result in hepatic failure or renal failure. We experienced a case of hereditary fructose intolerance presenting as recurrent hepatitis-like episodes. Detailed evaluation of her dietary habits revealed her avoidance of sweetened foods and fruits. Genetic analysis of ALDOB revealed that she is a homozygote for a novel frameshifting mutation c[758_759insT]+[758_759insT] (p.[val25 3fsX24]+[val253fsX24]). This report is the first of a Korean patient diagnosed with hereditary fructose intolerance using only molecular testing without undergoing intravenous fructose tolerance test or enzyme assay.


Asunto(s)
Niño , Humanos , Pruebas de Enzimas , Conducta Alimentaria , Mutación del Sistema de Lectura , Fructosa , Intolerancia a la Fructosa , Fructosa-Bifosfato Aldolasa , Fructosafosfatos , Frutas , Hepatitis , Hepatomegalia , Homocigoto , Hipoglucemia , Ictericia , Hígado , Fallo Hepático , Insuficiencia Renal
2.
Acta Pharmaceutica Sinica ; (12): 1291-1300, 2011.
Artículo en Chino | WPRIM | ID: wpr-232995

RESUMEN

Fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme involved in the pathway of gluconeogenesis, can catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate. Upon inhibiting the activity of FBPase, the production of endogenous glucose can be decreased and the level of blood glucose lowered. Therefore, inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes. Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.


Asunto(s)
Animales , Humanos , Adenosina Monofosfato , Química , Sitio Alostérico , Sitios de Unión , Glucemia , Metabolismo , Diabetes Mellitus Tipo 2 , Sangre , Inhibidores Enzimáticos , Química , Farmacología , Fructosa-Bifosfatasa , Química , Metabolismo , Fructosadifosfatos , Metabolismo , Fructosafosfatos , Metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA